J&J Medical Connect
SPRAVATO®

(esketamine)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

Maintenance Dose of SPRAVATO in SUSTAIN Clinical Trials

Last Updated: 11/18/2026

SUMMARY

Click on the following links to related sections within the document: Clinical Studies.
Abbreviations:
AD, antidepressant; MADRS, Montgomery-Åsberg Depression Rating Scale.
aDaly (2019).1 bWajs (2020).2 cData on File (2018).3 dZaki (2025).4 eThe oral AD utilized was sertraline, venlafaxine, escitalopram, or duloxetine; the same oral AD treatment started on day 1 of the induction phase was continued through maintenance.

PRODUCT LABELING

Click on the following links to related sections within the document: Clinical Studies.
Abbreviations:
AD, antidepressant; HCP, healthcare professional; MDD, major depressive disorder.
aSPRAVATO (esketamine) nasal spray [Prescribing Information].5 bDosing frequency should be individualized to the least frequent dosing to maintain remission/response.

Clinical Studies

SPRAVATO Dose Distribution and Dosing Frequency in SUSTAIN-1 Study

In a phase 3, double-blind, active-controlled, multicenter, long-term, maintenance-of-effect study, starting from week 8, an algorithm (based on the Montgomery-Åsberg Depression Rating Scale [MADRS]) was used to determine the dosing frequency for SPRAVATO. Patients in remission (i.e., MADRS total score was ≤12) were dosed every other week; however, if the MADRS total score increased to >12, then the frequency was increased to weekly dosing for the next 4 weeks, with the objective of maintaining the patient on the lowest dosing frequency to maintain response/remission.1

Of the patients randomized to SPRAVATO, 60.5% received 84 mg and 39.5% received 56 mg dose.3,6 For dosing frequency, see Table: Dosing Frequency Used the Majority of Time During the Maintenance Phase.


Dosing Frequency Used the Majority of Time During the Maintenance Phase3
Stable Remitters
Stable Responders
SPRAVATO + Oral AD (N=90)
Oral AD + Placebo Nasal Spray (N=86)
SPRAVATO + Oral AD (N=62)
Oral AD + Placebo Nasal Spray (N=59)
Majority dosing frequency
Weekly
21 (23.3%)
27 (31.4%)
34 (54.8%)
36 (61.0%)
Every other week
62 (68.9%)
48 (55.8%)
21 (33.9%)
19 (32.2%)
Weekly or every other week
7 (7.8%)
11 (12.8%)
7 (11.3%)
4 (6.8%)
Abbreviation: AD, antidepressant.
The oral AD utilized was sertraline, venlafaxine, escitalopram, or duloxetine. The same oral AD treatment started on day 1 of the induction phase was continued through maintenance.

In this study, 31.6% of patients received SPRAVATO for >6 months and 7.9% of patients received SPRAVATO for >1 year in the maintenance phase.3

SPRAVATO Dose Distribution and Dosing Frequency in SUSTAIN-2 Study

In a phase 3, open-label, multicenter, long-term, safety study, starting from week 9 to week 52 of the optimization/maintenance phase, SPRAVATO was administered either weekly or every other week depending on the MADRS score (every other week for MADRS total score of ≤12 and weekly for MADRS total score >12).2 A dose increase was not permitted after week 8. If needed for tolerability, a dose reduction by 28 mg from the previous dose was permitted from week 9 through the end of the maintenance phase.2,7

Of 603 patients in the optimization/maintenance phase (weeks 5-52), 24% of patients received weekly dosing, 38.1% were maintained on every-other-week dosing, and 37.8% switched back and forth between weekly and every-other-week dosing. The final SPRAVATO dose was 56 mg in 45.6%, 84 mg in 50.2%, and 28 mg in 4% of patients, and median SPRAVATO exposure was 22.9 weeks.2

Nijs et al (2020)8 conducted a post hoc analysis of SUSTAIN-2 to assess the effect of dosing frequency changes on efficacy assessed by Clinical Global Impression-Severity (CGIS) score. Patients worsening on every-other-week SPRAVATO dosing experienced better outcomes from weekly dosing. See Table: CGI-S Score After Change in Treatment Frequency. The authors note that the treatment protocol allowed changes in dosing frequency no more often than every 4 weeks, with a maximum of 3 changes; however, in clinical practice, they recommend a prompt increase in dosing frequency if a worsening of depressive symptoms is observed sooner than 4 weeks after switching from every week to every other week.


CGI-S Score After Change in Treatment Frequency8
Dosing Frequency Change (N=580)a
Improvedb
Maintained Benefitc
Remained Unchangedd
Worsenede
Twice weekly → weekly
26%
50%
-
24%
Weekly → Every other week
19%
49%
-
32%
Every other week → weekly
47%
-
43%
10%
Abbreviations: CGI-S, Clinical Global Impression-Severity; MADRS, Montgomery-Åsberg Depression Rating Scale.
Patients were classified based on change in CGI-S scores from baseline at the time when treatment frequency was changed to 4 weeks post change in treatment frequency. One-point change in CGI-S score was assumed to be clinically meaningful.
aRepresents number of responders (≥50% reduction in MADRS total score) at the end of the induction phase.bChange in CGI-S ≤-1.
cCGI-S = 0 after dose frequency was reduced.
dCGI-S = 0 after dose frequency was increased.
eChange in CGI-S ≥1.

SPRAVATO Dose Distribution and Dosing Frequency in SUSTAIN-3 Study

In a phase 3, open-label extension study evaluating the long-term safety and efficacy of individualized, intermittently dosed SPRAVATO in patients with treatment-resistant depression (N=1148), median exposure to SPRAVATO was 45.8 months, with the duration of exposure ranging from ≥3 years (63% of patients) to ≥5 years (28% of patients); total exposure was 3777 cumulative patient-years. During the maintenance phase, SPRAVATO was most frequently administered weekly (approximately 40%-50% of patients), followed by every other week (approximately 35%-45% of patients), and every 4 weeks (approximately ≤25% of patients by the end of study). The final maintenance dose was 84 mg for most patients (64.4%), while 56 mg and 28 mg were received by 33.0% and 2.5% of patients, respectively.4 

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 22 October 2026.

References

1 Daly EJ, Trivedi MH, Janik A, et al. Protocol to: Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893-903.  
2 Wajs E, Aluisio L, Holder R, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020;81(3):19m12891.  
3 Data on File. Esketamine. Clinical Overview. Janssen Research & Development, LLC; 2018.  
4 Zaki N, Chen L, Lane R, et al. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. Int J Neuropsychopharmacol. 2025;28(6):pyaf027.  
5 SPRAVATO (esketamine) nasal spray [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf
6 Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893-903.  
7 Data on File. Esketamine. Clinical Study Report ESKETINTRD3004. Janssen Research & Development, LLC. EDMS-ERI-146551506; 2018.  
8 Nijs M, Wajs E, Aluisio L, et al. Managing esketamine treatment frequency toward successful outcomes: analysis of phase 3 data. Int J Neuropsychopharmacol. 2020;23(7):426-433.   

Would you like to clear and leave your conversation? Message history will be lost.